(688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares
Filed with SSE · Stock code 688091 · · 3 pages · Chinese
Summary by 6ix AI
Shanghai Yizhong Pharmaceutical Co. Ltd. has announced progress on its share repurchase plan, detailing the number of shares repurchased and the total amount spent as of the end of September. The announcement also outlines the timeline and regulatory compliance related to the share repurchase process.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shanghai Yizhong Pharmaceutical Co. Ltd. on 6ix
Story so far
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
- Announcement on the Grant of Reserved Restricted Shares to Participants under the 2026 Restricted Share Incentive Plan
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial for the Investigational Innovative Drug YXC-002
Earlier from Shanghai Yizhong Pharmaceutical
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
- Announcement on the Grant of Reserved Restricted Shares to Participants under the 2026 Restricted Share Incentive Plan
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial for the Investigational Innovative Drug YXC-002
- Voluntary Disclosure Announcement on Receipt of a Notice of Approval for Drug Clinical Trial for the Investigational Innovative Drug YXC-001
- Announcement on the Company and Its Wholly-owned Subsidiaries Using Certain Idle Raised Funds for Cash Management
Later from Shanghai Yizhong Pharmaceutical
- (688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Implementation Results of Share Repurchase and Share Changes
- (688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of Completion of First Dosing in the First Dose Cohort of the Phase I Clinical Trial of Innovative Drug YXC-001
Follow Shanghai Yizhong Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai Yizhong Pharmaceutical